First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid

被引：0
|
作者：
Lin, F. [1 ]
Huang, Y. [2 ]
Huang, Y. [2 ]
Lu, Y. [2 ]
Rao, X. [3 ]
Wang, X. [2 ]
Wang, F. [2 ]
Huang, X. [2 ]
机构：
[1] Tongji Univ, Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China
[2] Hangzhou Adcoris Biopharma Co Ltd, Translat Med, Hangzhou, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Med Oncol, Nanchang, Jiangxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335P
引用
收藏
页码：S354 / S355
页数：2
相关论文
共 50 条
  • [41] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
    Strickler, John H.
    Weekes, Colin D.
    Nemunaitis, John
    Ramanathan, Ramesh K.
    Heist, Rebecca S.
    Morgensztern, Daniel
    Angevin, Eric
    Bauer, Todd M.
    Yue, Huibin
    Motwani, Monica
    Parikh, Apurvasena
    Reilly, Edward B.
    Afar, Daniel
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
  • [42] First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
    Demetri, George D.
    Luke, Jason J.
    Hollebecque, Antoine
    Powderly, John D.
    Spira, Alexander I.
    Subbiah, Vivek
    Naumovski, Louie
    Chen, Chris
    Fang, Hua
    Lai, Dominic W.
    Yue, Huibin
    Polepally, Akshanth R.
    Purcell, James W.
    Robinson, Randy
    Sharma, Padmanee
    Allison, James P.
    Tolcher, Anthony
    Villalobos, Victor M.
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3556 - 3566
  • [43] First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
    Chandana, Sreenivasa R.
    Choudhury, Noura J.
    Dowlati, Afshin
    Chiang, Anne C.
    Garmezy, Benjamin
    Kim, Joo-Hang
    Byers, Lauren Averett
    Ahn, Myung-Ju
    Kim, Tae Min
    Kim, Young-Chul
    Han, Ji-Youn
    Bar, Jair
    Zha, Jiuhong
    Henner, William
    Robinson, Randy
    Kohlhapp, Fred
    Hingorani, Pooja
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
    Demetri, George D.
    Luke, Jason J.
    Hollebecque, Antoine
    Powderly, John D.
    Spira, Alexander I.
    Subbiah, Vivek
    Lai, Dominic W.
    Yue, Huibin
    Kasichayanula, Sreeneeranj
    Gulbranson, Scott
    Purcell, James
    Myzak, Melinda
    Robinson, Randy
    Villalobos, Victor Manuel
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+metastatic breast cancer
    Krop, I. E.
    Beeram, M.
    Modi, S.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Burris, H. A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 219 - 219
  • [46] Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+metastatic breast cancer (MBC): phase I and phase II trial results
    Burris, H., III
    Vukelja, S.
    Krop, I.
    Modi, S.
    Klencke, B.
    Girish, S.
    Sliwkowski, M. X.
    Dresser, M.
    Phillips, G. L.
    Rugo, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 266 - 267
  • [47] A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)
    Hollebecque, Antoine
    Lopez, Juanita
    Piha-Paul, Sarina
    Dowlati, Afshin
    Patnaik, Amita
    Galvao, Vladimir
    Buckorny, Bruno
    Sehgal, Kartik
    Kingsley, Edwin
    Sanborn, Rachel
    Peters, Solange
    Sun, Yan
    Patilea-Vrana, Gabriela
    Nazarenko, Natalya
    Calvo, Emiliano
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A763 - A763
  • [48] Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer br
    Zhang, Jian
    Ji, Dongmei
    Shen, Weina
    Xiao, Qin
    Gu, Yajia
    'Shaughnessy, Joyce
    Hu, Xichun
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4212 - 4221
  • [49] First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors
    Shimizu, Toshio
    Fujiwara, Yutaka
    Yonemori, Kan
    Koyama, Takafumi
    Sato, Jun
    Tamura, Kenji
    Shimomura, Akihiko
    Ikezawa, Hiroki
    Nomoto, Maiko
    Furuuchi, Keiji
    Nakajima, Ryo
    Miura, Takuma
    Yamamoto, Noboru
    CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3905 - 3915
  • [50] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Sarina A. Piha-Paul
    Analía Azaro
    Hendrik Tobias Arkenau
    Do-Youn Oh
    Matthew D. Galsky
    Sumanta Kumar Pal
    Kensuke Hamada
    Yaohua He
    Ikuo Yamamiya
    Karim A Benhadji
    Antoine Hollebecque
    Investigational New Drugs, 2021, 39 : 1324 - 1334
12345